SYRE Q4 2024 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$61M

Net Income

-$56M

EPS (Diluted)

$-0.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$608M

Total Liabilities

$91M

Stockholders' Equity

$518M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$61M	-$46M	-33.4%
Net Income	-$56M	-$63M	+10.9%